A
Anton Schattenberg
Researcher at Radboud University Nijmegen
Publications - 62
Citations - 3227
Anton Schattenberg is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Transplantation & Autologous stem-cell transplantation. The author has an hindex of 26, co-authored 62 publications receiving 2980 citations. Previous affiliations of Anton Schattenberg include Radboud University Nijmegen Medical Centre.
Papers
More filters
Journal ArticleDOI
Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis: A Randomized Clinical Trial
J.M. van Laar,Dominique Farge,Jacob K. Sont,Kamran Naraghi,Zora Marjanovic,Jérôme Larghero,Annemie J. Schuerwegh,Erik W.A. Marijt,Madelon C. Vonk,Anton Schattenberg,Marco Matucci-Cerinic,A E Voskuyl,A.A. van de Loosdrecht,Thomas Daikeler,Ina Kötter,Marc Schmalzing,Thierry Martin,Bruno Lioure,S.M. Weiner,Alexander Kreuter,Christophe Deligny,Jean-Marc Durand,Paul Emery,Klaus P Machold,F. Sarrot-Reynauld,Klaus Warnatz,Daniel Adoue,Joël Constans,Hans-Peter Tony,N. Del Papa,A Fassas,Andrea Himsel,David Launay,A. Lo Monaco,P. Philippe,Isabelle Quéré,E. Rich,Rene Westhovens,Bridget Griffiths,Riccardo Saccardi,F.H.J. van den Hoogen,Willem E. Fibbe,Gérard Socié,Alois Gratwohl,Alan Tyndall +44 more
TL;DR: Among patients with early diffuse cutaneous systemic sclerosis, HSCT was associated with increased treatment-related mortality in the first year after treatment, however, HCST conferred a significant long-term event-free survival benefit.
Journal ArticleDOI
Allogeneic bone marrow transplantation for low-grade lymphoma.
Koen van Besien,Kathleen A. Sobocinski,Philip A. Rowlings,Sandra C. Murphy,James O. Armitage,Michael R. Bishop,Ok-Kyong Chaekal,Robert Peter Gale,John P. Klein,Hillard M. Lazarus,Philip L. McCarthy,John M. M. Raemaekers,Josy Reiffers,G. L. Phillips,Anton Schattenberg,Leo F. Verdonck,Julie M. Vose,Mary M. Horowitz +17 more
TL;DR: It is concluded that high-dose therapy followed by transplantation from a HLA-identical sibling leads to prolonged survival in some patients with advanced low-grade lymphoma.
Journal ArticleDOI
Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR Registry
Dominique Farge,Jakob Passweg,J.M. van Laar,Zora Marjanovic,C. Besenthal,Jürgen Finke,Hans-Hartmut Peter,Ferdinand C. Breedveld,Willem E. Fibbe,Carol M. Black,Christopher P. Denton,I. Koetter,Francesco Locatelli,Alberto Martini,Anton Schattenberg,F.H.J. van den Hoogen,L. B. A. Van De Putte,Francesco Lanza,Renate Arnold,P. A. Bacon,Sarah J. Bingham,Fabio Ciceri,B. Didier,José Luis Díez-Martín,Paul Emery,W. Feremans,Bernd Hertenstein,Falk Hiepe,R. Luosujarvi,A. Leon Lara,Alberto M. Marmont,Angelina Martínez,H. Pascual Cascon,Chiara Bocelli-Tyndall,Eliane Gluckman,Alois Gratwohl,A Tyndall +36 more
TL;DR: It was shown that response in two thirds of the patients after HSCT was durable with an acceptable TRM and prospective, randomised trials are proceeding.
Journal ArticleDOI
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose
Cesare Guglielmi,William Arcese,Francesco Dazzi,Ronald Brand,Donald Bunjes,Leo F. Verdonck,Anton Schattenberg,Hans-Jochem Kolb,Per Ljungman,Agnès Devergie,Andrea Bacigalupo,M. Gómez,Mauricette Michallet,Ahmet H. Elmaagacli,Alois Gratwohl,Jane F. Apperley,Dietger Niederwieser +16 more
TL;DR: The results suggest that the first DLI dose should not exceed 0.2 x 10(8) mononuclear cells/kg, and lower ICD was associated with less GVHD, less myelosuppression, same response rate, better survival, better failure-free survival, and less DLI-related mortality.
Journal ArticleDOI
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma
Henk M. Lokhorst,K.L. Wu,Leo F. Verdonck,Laurens L. Laterveer,Niels W.C.J. van de Donk,Marinus H. J. van Oers,Jan J. Cornelissen,Anton Schattenberg +7 more
TL;DR: It is found that acute and chronic graft-versus-host disease (GVHD) observed in 57% and 47% of patients, respectively, following DLI were the strongest predictors for response, suggesting that targets for GVHD and GVM are identical.